Skip to main content
Equibles

AAREYDRUGS · Aarey Drugs & Pharmaceuticals Limited · Financials

Use AAREYDRUGS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AAREYDRUGS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
115.15 INR +1.04 (+0.91%) At close · Nov 13
Rebalance outlook locked
Market Cap
3.26B INR
Shares
28.35M
Volume · Nov 13 217.27K Avg daily vol (3M) 227.51K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
4.72B -0.4%
FY2026 Revenue FY2022–FY2026
Net Income
39.68M -1.4%
FY2026 Net Income FY2022–FY2026
Operating Cash Flow
101.39M +5%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022
INR 4.15B 4.72B 4.74B 3.96B 624.71M 4.93B
INR 32.15M 28.53M 19.45M 16.98M 7.1M 19.88M
INR 56.39M 50.02M 40.17M 43.75M 5.51M 20M
INR 42.01M 54.14M 61.02M 53.43M 7.46M 100.27M
INR 270K 14.47M 20.78M 6.59M 2.51M 24.99M
INR 41.74M 39.68M 40.24M 46.84M 4.95M 75.28M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 0 in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.